Previous 10 | Next 10 |
Heat Biologics (HTBX) has fallen ~10.7% in the premarket after the company announced that additional preclinical results of its COVID-19 vaccine candidate were published in Frontiers in Immunology, a peer-reviewed journal.Heat Biologics’ COVID-19 vaccine candid...
T2 Biosystems (TTOO) -20% despite strong Q4 & FY20 prelims.AIkido Pharma (AIKI) -18%.Seanergy Maritime Holdings (SHIP) -18%.Celsion CLSN -15%.Recon Technology (RCON) -15%.TransEnterix (TRXC) -14% after $69.25M capital raise.Ocugen (OCGN) -14%.BIOLASE (BIOL) -15%.P...
Spike specific CD8+ and CD4+ T-cell memory responses observed 30- and 60- days post vaccination DURHAM, NC / ACCESSWIRE / January 27, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX) , a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to mod...
Heat Biologics (HTBX) is up ~9.0% in the premarket after the company announced that it has engaged CRS Crossroads Strategies, LLC, to assist in advancing government collaborations.With effect from February 01, CRS Crossroads, a bipartisan government relations firm based in...
Heat Biologics, Inc. is a clinical-stage biopharmaceutical stage company focused on developing immune therapies and vaccines. Heat Biologics' pipeline consists of three clinical-stage therapeutics and 1 pre-clinical (COVID-19 vaccine). Heat Biologics' lead therapeutic is HS-110 (viage...
DURHAM, NC / ACCESSWIRE / January 20, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, to...
DURHAM, NC / ACCESSWIRE / January 19, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX) , a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, ...
DURHAM, NC / ACCESSWIRE / January 11, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX) , a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, ...
DURHAM, NC / ACCESSWIRE / January 8, 2021 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, has...
Zolovax, Inc., a wholly-owned subsidiary of Heat Biologics (HTBX), has entered into an exclusive license agreement with the University of Miami for its UMIP-510 platform. Heat Biologics has also promoted William Ostrander as Chief Financial Officer with effect from January 4, 2021.The ag...
News, Short Squeeze, Breakout and More Instantly...
DURHAM, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) , (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the successful execution of its first...
DURHAM, N.C., July 17, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today announced that the Company’s Board of ...
DURHAM, N.C., June 17, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today reported that it received notice ...